Corbus Pharmaceuticals announced the Last Patient First Visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity treatment, with the 16-week study on track for completion in summer 2026.
Key takeaways
Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913.
Trial is 16-week, double-blind, placebo-controlled study in 240 obese, non-diabetic participants.
Includes placebo cohort and CRB-913 cohorts at 20 mg, 40 mg, 60 mg with dose titration starting at 20 mg/day.
Study on track to complete in summer 2026; participants dosed for 3 months plus 1-month monitoring.
Phase 1a showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort at 150 mg/day.